Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if rifaximin, administered daily has an
effect on the cytochrome P450 (CYP) isoenzyme 3A4, by examining any changes in the
pharmacokinetics of midazolam (a CYP3A4 substrate), when co-administered.
Phase:
Phase 1
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.